A research team has published a study in Nature Communications detailing the development of a novel genetically encoded ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.

If I look at AMR, for example, I think this is a huge opportunity for Biogen. And we saw 80% resolution of AMR in Phase 2 trials. So, we have a high level of confidence in that. But of course ...

Biogen’s research strategy is oriented around a clear framework for identifying high value drug candidates. Going forward, the organization is laser focused on pursuing and advancing programs ...

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS ...

Biogen Inc. closed 48.82% short of its 52-week high of $238.00, which the company reached on July 12th.

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...